|
1.
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar
|
|
2.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
3.
|
Liakakos T, Katsios C and Roukos DH:
Gastroesophageal junction carcinoma multimodal treatment:
standards, debate and new therapeutic options. Expert Rev
Gastroenterol Hepatol. 5:1–4. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Ilson DH: Esophageal cancer chemotherapy:
recent advances. Gastrointest Cancer Res. 2:85–92. 2008.
|
|
5.
|
Ku GY and Ilson DH: Esophageal cancer:
adjuvant therapy. Cancer J. 13:162–167. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Okines AF and Cunningham D: Trastuzumab: a
novel standard option for patients with HER-2-positive advanced
gastric or gastro-oesophageal junction cancer. Therap Adv
Gastroenterol. 5:301–318. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Dai GH, Shi Y, Chen L, Lv YL and Zhong M:
Trastuzumab combined with docetaxel-based regimens in previously
treated metastatic gastric cancer patients with HER2
over-expression. Hepatogastroenterology. 59:2439–2444.
2012.PubMed/NCBI
|
|
8.
|
Hicks DG and Whitney-Miller C: HER2
testing in gastric and gastroesophageal junction cancers: a new
therapeutic target and diagnostic challenge. Appl Immunohistochem
Mol Morphol. 19:506–508. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Lordick F: Trastuzumab: a new treatment
option for HER2-positive metastatic gastric and gastroesophageal
junction cancer. Future Oncol. 7:187–199. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Reichelt U, Duesedau P, Tsourlakis MCh, et
al: Frequent homogeneous HER-2 amplification in primary and
metastatic adenocarcinoma of the esophagus. Mod Pathol. 20:120–129.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Gabbert HE, Nakamura Y, Shimoda T, Field
JK, Hainaut P and Inoue H: Squamous cell carcinoma of the
oesophagus. World Health Organization Classification of Tumors.
Hamilton SR and Aaltonen LA: 1st edition. IARC Press; Lyon: pp.
16–17. 2000
|
|
12.
|
Huang J: Esophageal cancer. Manual of
Medical Oncology. Sun Y and Shi YK: 5th edition. The People’s
Medical Publishing House; Beijing: pp. 466–475. 2007
|
|
13.
|
Wolff AC, Hammond ME, Schwartz JN, et al:
American Society of Clinical Oncology/College of American
Pathologists guideline recommendations for human epidermal growth
factor receptor 2 testing in breast cancer. J Clin Oncol.
25:118–145. 2007. View Article : Google Scholar
|
|
14.
|
Dent R, Trudeau M, Pritchard KI, et al:
Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): a phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar
|
|
16.
|
Koltz BR, Hicks DG and Whitney-Miller CL:
HER2 testing in gastric and esophageal adenocarcinoma: new
diagnostic challenges arising from new therapeutic options. Biotech
Histochem. 87:40–45. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Sato-Kuwabara Y, Neves JI, Fregnani JH,
Sallum RA and Soares FA: Evaluation of gene amplification and
protein expression of HER-2/neu in esophageal squamous cell
carcinoma using Fluorescence in situ Hybridization (FISH) and
immunohistochemistry. BMC Cancer. 9:62009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Wei Q, Chen L, Sheng L, Nordgren H, Wester
K and Carlsson J: EGFR, HER2 and HER3 expression in esophageal
primary tumours and corresponding metastases. Int J Oncol.
31:493–499. 2007.PubMed/NCBI
|
|
19.
|
Wu D, Xu J, Yu G, et al: Expression status
of fatty acid synthase (FAS) but not HER2 is correlated with the
differentiation grade and prognosis of esophageal carcinoma.
Hepatogastroenterology. Jun 18–2012.(Epub ahead of print).
|
|
20.
|
Yoon HH, Shi Q, Sukov WR, et al:
Association of HER2/ErbB2 expression and gene amplification with
pathologic features and prognosis in esophageal adenocarcinomas.
Clin Cancer Res. 18:546–554. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Zhan N, Dong WG, Tang YF, Wang ZS and
Xiong CL: Analysis of HER2 gene amplification and protein
expression in esophageal squamous cell carcinoma. Med Oncol.
29:933–940. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Varshney D, Zhou YY, Geller SA and Alsabeh
R: Determination of HER-2 status and chromosome 17 polysomy in
breast carcinomas by comparing HercepTest and PathVysion FISH
assay. Am J Clin Pathol. 121:70–77. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Ross JS: Point: Fluorescence in
situ hybridization is the preferred approach over
immunohistochemistry for determining HER2 status. Clin Chem.
57:980–982. 2011.
|
|
24.
|
Pazo Cid RA and Antón A: Advanced
HER2-positive gastric cancer: Current and future targeted
therapies. Crit Rev Oncol Hematol. 85:350–362. 2013.PubMed/NCBI
|
|
25.
|
Terashima M, Kitada K, Ochiai A, et al:
Impact of expression of human epidermal growth factor receptors
EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin
Cancer Res. 18:5992–6000. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Shitara K, Yatabe Y, Matsuo K, et al:
Prognosis of patients with advanced gastric cancer by HER2 status
and trastuzumab treatment. Gastric Cancer. Jul 14–2012.(Epub ahead
of print).
|
|
27.
|
Kim JW, Im SA, Kim M, et al: The
prognostic significance of HER2 positivity for advanced gastric
cancer patients undergoing first-line modified FOLFOX-6 regimen.
Anticancer Res. 32:1547–1553. 2012.PubMed/NCBI
|
|
28.
|
Barros-Silva JD, Leitão D, Afonso L, et
al: Association of ERBB2 gene status with histopathological
parameters and disease specific survival in gastric carcinoma
patients. Br J Cancer. 100:487–493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Rüschoff J: Adenocarcinoma of the GEJ:
gastric or oesophageal cancer? Recent Results Cancer Res.
196:107–113. 2012.
|
|
30.
|
Suh YS, Han DS, Kong SH, et al: Should
adenocarcinoma of the esophagogastric junction be classified as
esophageal cancer? A comparative analysis according to the seventh
AJCC TNM classification. Ann Surg. 255:908–915. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Lorenzen S and Lordick F: How will human
epidermal growth factor receptor 2-neu data impact clinical
management of gastric cancer? Curr Opin Oncol. 23:396–402. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Fassan M, Ludwig K, Pizzi M, et al: Human
epithelial growth factor receptor 2 (HER2) status in primary and
metastatic esophagogastric junction adenocarcinomas. Hum Pathol.
43:1206–1212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Wainberg ZA, Lin LS, DiCarlo B, et al:
Phase II trial of modified FOLFOX6 and erlotinib in patients with
metastatic or advanced adenocarcinoma of the oesophagus and
gastro-oesophageal junction. Br J Cancer. 105:760–765. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Thompson SK, Sullivan TR, Davies R and
Ruszkiewicz AR: Her-2/neu gene amplification in esophageal
adenocarcinoma and its influence on survival. Ann Surg Oncol.
18:2010–2017. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Grávalos C, Gómez-Martín C, Rivera F, Alés
I, et al: Phase II study of trastuzumab and cisplatin as first-line
therapy in patients with HER2-positive advanced gastric or
gastroesophageal junction cancer. Clin Transl Oncol. 13:179–184.
2011.PubMed/NCBI
|
